Gemmus Pharma, a San Francisco, California-based biotechnology company developing an improved host-targeted treatment for flu, closed a $3.3m Series B funding.
Backers included the Life Science Angels (LSA), BlueTree Allied Angels, The Angels’ Forum, Tech Coast Angels and Wilmington Investor Network, as well as several individual investors.
The company intends to use the funds to complete production and toxicology studies for an IND filing by the end of the year.
Led by Daryl Faulds, PhD, CEO, Gemmus focuses on the development of innovative pharmaceutical products for the treatment of infectious diseases by modulating the host response to the disease.
Founded in 2007, the company is advancing GP1681, an orally available eicosanoid being developed for the treatment of moderate to severe symptoms of influenza infection.
Gemmus is a member of the QB3 network, a San Francisco Bay Area Biotech incubator associated with UCSF Mission Bay campus.